Non-Hodgkin lymphomas are heterogeneous lymphoid malignancies that are managed with a range of therapeutic goals. Aggressive B-cell lymphomas such as diffuse large B-cell lymphoma (DLBCL) are typically treated with curative intent, and frontline therapy can achieve a cure in up to 70% of patients. In the current rituximab era, however, patients with refractory DLBCL or those who relapse after therapy are not commonly cured with standard approaches such as autologous stem cell transplant. Novel therapies are emerging for DLBCL that target mechanisms of cellular resistance, but they take years to develop and benefit only subsets of patients.
Incurable lymphomas, such as follicular lymphoma (FL) and mantle cell lymphoma (MCL), exhibit a perpetually relapsing disease course, and the primary goal of therapy is induction of deep and durable remissions.[4,5] Increasingly, patients with these lymphomas are treated for extended periods with maintenance therapies. Clinical decisions regarding the duration of maintenance therapy for indolent lymphomas are usually made empirically and without direct measurement of disease burden or molecular aberrations within the tumor.
The gold standard for initial staging, response assessment, and surveillance monitoring in non-Hodgkin lymphomas is assessment with imaging modalities such as computed tomography (CT) and fluorodeoxyglucose (FDG) positron emission tomography (PET). Despite widespread use, imaging scans have important drawbacks, including radiation exposure, cost, and low tumor specificity.[7-10] In addition, PET scans do not perform well as surveillance tools, and there is concern regarding the use of imaging for detection of asymptomatic relapse.[11,12] PET scans have also been extensively tested as interim biomarkers for purposes of tailoring therapy. Despite initial enthusiasm, two large studies failed to demonstrate a benefit to switching therapy in patients with DLBCL on the basis of interim PET (iPET) results.[13,14]
Precision medicine approaches to non-Hodgkin lymphomas consider the molecular profile of the tumor when targeted therapies are selected. Currently, the standard method for determining tumor genetic profiles requires tissue biopsies. Tissue biopsies, however, contain procedural risks, are subject to sampling error, and cannot account for spatial tumor heterogeneity. In view of these limitations, genetic profiles obtained from peripheral blood are of great interest.
Novel sequencing-based assays can detect cell-free circulating tumor DNA (ctDNA), which encodes the immunoglobulin gene sequence unique to individual B-cell lymphomas.[16-20] Assays involving ctDNA that detect somatic mutational profiles and that can serve as a “liquid biopsy” to monitor for the development of treatment-resistant clones are also being developed for non-Hodgkin lymphomas. Both patients with indolent non-Hodgkin lymphomas and those with aggressive non-Hodgkin lymphomas stand to benefit from advances in technologies that more precisely define disease relapse at earlier time points. Precision molecular monitoring of ctDNA offers lower detection limits than scans and may overcome the limitations of both imaging scans and tissue biopsies (Figure 1). In this review, we discuss the potential applications of monitoring ctDNA in patients with DLBCL, FL, and MCL.
Advances in Molecular Monitoring Methods for Non-Hodgkin Lymphomas
The quest to find tumor-specific molecules in the peripheral blood to monitor patients with non-Hodgkin lymphoma dates back decades. The principal barriers to widespread use have been difficulties in identifying appropriate targets with broad clinical applicability across all non-Hodgkin lymphoma subtypes. In specific subtypes, recurrent translocations can be detected in the blood by polymerase chain reaction (PCR)-based methods (Figure 2). These include the IGH-CCND1 translocation, t(11;14), in MCL and the IGH-BCL2 translocation, t(14;18), in FL. All patients with MCL and the majority of patients with FL harbor these respective translocations, which makes them attractive targets for molecular monitoring.[22,23] Allele-specific oligonucleotide PCR (ASO-PCR) techniques use patient-specific primers to detect and quantitate BCL2 and CCND1 rearrangements, with a limit of detection approaching 1 × 105 cells. Because of variations in breakpoint regions, however, PCR is not able to detect IGH-BCL2 translocations in the blood of all patients with FL. Furthermore, most non-Hodgkin lymphoma subtypes do not have recurrent translocations amenable to molecular monitoring. Given the need for patient-specific primers and the lack of universal applicability, ASO-PCR is considered laborious and not conducive to widespread use.
Tumor-specific DNA fragments can be detected noninvasively in the blood in both cellular (circulating tumor cells [CTCs]) and cell-free (ctDNA) forms (see Figure 2). In certain lymphomas, such as DLBCL, however, CTCs are rare, and recent data indicate a possible relationship between defective homing pathways and systemic dissemination.[24-26] Multiple studies have demonstrated higher levels of circulating cell-free DNA (cfDNA) in cancer patients than in healthy controls, which result from the constant shedding of DNA fragments into the peripheral blood from cancer cells undergoing apoptosis, secretion, and necrosis.[27-29] Since cfDNA can originate from both malignant and nonmalignant sources, assays for ctDNA must accurately discriminate the tumor-specific DNA fragments within the overall cfDNA concentration. ctDNA is therefore defined as the tumor-specific DNA sequences found in either the plasma or the serum of the blood and may represent as little as 0.01% of total cfDNA. An early study using real-time quantitative reverse transcriptase-PCR of the germline beta-globin gene revealed significantly higher median cfDNA levels in patients with DLBCL, MCL, and Hodgkin lymphoma than in healthy controls, with similar concentrations in patients with FL. This study was the first to validate ctDNA as a quantifiable tumor-specific biomarker in patients with non-Hodgkin lymphoma.
1. Roschewski M, Dunleavy K, Wilson WH. Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphoma. Leuk Lymphoma. 2014;55:2428-37.
2. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184-90.
3. Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma—treatment approaches in the molecular era. Nat Rev Clin Oncol. 2014;11:12-23.
4. Kahl BS, Yang DT. Follicular lymphoma: evolving therapeutic strategies. Blood. 2016;127:2055-63.
5. Perez-Galan P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood. 2011;117:26-38.
6. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059-68.
7. Brenner DJ, Hall EJ. Computed tomography—an increasing source of radiation exposure. N Engl J Med. 2007;357:2277-84.
8. Huntington SF, Svoboda J, Doshi JA. Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission. J Clin Oncol. 2015;33:1467-74.
9. Moskowitz CH, Schoder H, Teruya-Feldstein J, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol. 2010;28:1896-903.
10. Thompson CA, Ghesquieres H, Maurer MJ, et al. Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. J Clin Oncol. 2014;32:3506-12.
11. Cheah CY, Hofman MS, Dickinson M, et al. Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. Br J Cancer. 2013;109:312-7.
12. Armitage JO, Vose JM. To surveil or not to surveil. J Clin Oncol. 2015;33:3983-4.
13. Duehrsen U, Hüttmann A, Müller S, et al. Positron emission tomography (PET) guided therapy of aggressive lymphomas—a randomized controlled trial comparing different treatment approaches based on interim PET results (PETAL trial). Blood (ASH Annual Meeting Abstracts). 2014;124:abstr 391.
14. Sehn LH, Hardy ELG, Gill KK, et al. Phase 2 trial of interim PET scan-tailored therapy in patients with advanced stage diffuse large B-cell lymphoma (DLBCL) in British Columbia (BC). Blood (ASH Annual Meeting Abstracts). 2014;124:abstr 392.
15. Alizadeh AA, Aranda V, Bardelli A, et al. Toward understanding and exploiting tumor heterogeneity. Nat Med. 2015;21:846-53.
16. Armand P, Oki Y, Neuberg DS, et al. Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2013;163:123-6.
17. Roschewski M, Dunleavy K, Pittaluga S, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol. 2015;16:541-9.
18. Kurtz DM, Green MR, Bratman SV, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood. 2015;125:3679-87.
19. Ladetto M, Bruggemann M, Monitillo L, et al. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia. 2014;28:1299-307.
20. Sarkozy C, Huet S, Carlton V, et al. Quantitative assessment of circulating clonal IG-VDJ sequences in plasma of follicular lymphoma at diagnosis is highly predictive of progression free survival (PFS). Blood (ASH Annual Meeting Abstracts). 2015;126:abstr 2675.
21. Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32:579-86.
22. Raffeld M, Jaffe ES. Bcl-1, t(11;14), and mantle cell-derived lymphomas. Blood. 1991;78:259-63.
23. Weinberg OK, Ai WZ, Mariappan MR, et al. “Minor” BCL2 breakpoints in follicular lymphoma: frequency and correlation with grade and disease presentation in 236 cases. J Mol Diagn. 2007;9:530-7.
24. Muppidi JR, Schmitz R, Green JA, et al. Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma. Nature. 2014;516:254-8.
25. Muringampurath-John D, Jaye DL, Flowers CR, et al. Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase. Br J Haematol. 2012;158:608-14.
26. Mancuso P, Calleri A, Antoniotti P, et al. If it is in the marrow, is it also in the blood? An analysis of 1,000 paired samples from patients with B-cell non-Hodgkin lymphoma. BMC Cancer. 2010;10:644.
27. Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61:1659-65.
28. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37:646-50.
29. Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer—a survey. Biochim Biophys Acta. 2007;1775:181-232.
30. Mandel P, Metais P. Les acides nucléiques du plasma sanguin chez l’homme. C R Seances Soc Biol Fil. 1948;142:241-3.
31. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011;11:426-37.
32. Hohaus S, Giachelia M, Massini G, et al. Cell-free circulating DNA in Hodgkin’s and non-Hodgkin’s lymphomas. Ann Oncol. 2009;20:1408-13.
33. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24.
34. Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368:1199-209.
35. Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20:548-54.
36. Guibert N, Pradines A, Casanova A, et al. Detection and monitoring of the BRAF mutation in circulating tumor cells and circulating tumor DNA in BRAF-mutated lung adenocarcinoma. J Thorac Oncol. 2016 May 7. [Epub ahead of print]
37. Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14:985-90.
38. Sausen M, Phallen J, Adleff V, et al. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat Commun. 2015;6:7686.
39. Tie J, Wang Y, Tomasetti C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8:346ra92.
40. Faham M, Zheng J, Moorhead M, et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood. 2012;120:5173-80.
41. Roschewski M, Staudt LM, Wilson WH. Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma. Blood. 2016;127:3127-32.
42. Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009;27:1209-13.
43. Armitage JO, Longo DL. Is watch and wait still acceptable for patients with low-grade follicular lymphoma? Blood. 2016;127:2804-8.
44. Portlock CS, Rosenberg SA. No initial therapy for stage III and IV non-Hodgkin’s lymphomas of favorable histologic types. Ann Intern Med. 1979;90:10-3.
45. Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol. 2009;27:1202-8.
46. Roulland S, Kelly RS, Morgado E, et al. t(14;18) translocation: a predictive blood biomarker for follicular lymphoma. J Clin Oncol. 2014;32:1347-55.
47. Scherer F, Kurtz DM, Newman AM, et al. Noninvasive genotyping and assessment of treatment response in diffuse large B cell lymphoma. Blood (ASH Annual Meeting Abstracts). 2015;126:abstr 114.
48. Rasi S, Monti S, Zanni M, et al. Liquid biopsy as a tool for monitoring the genotype of diffuse large B-cell lymphoma. Blood (ASH Annual Meeting Abstracts). 2015;126:abstr 127.
49. Pentsova EI, Shah RH, Tang J, et al. Evaluating cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid. J Clin Oncol. 2016 May 9. [Epub ahead of print]
50. Zohren F, Bruns I, Pechtel S, et al. Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy. Blood. 2015;126:1407-14.
51. Lin C, Itti E, Haioun C, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med. 2007;48:1626-32.
52. Cashen AF, Dehdashti F, Luo J, et al. 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. J Nucl Med. 2011;52:386-92.
53. Kurtz DM, Scherer F, Newman AM, et al. Dynamic noninvasive genomic monitoring for outcome prediction in diffuse large B-cell lymphoma. Blood (ASH Annual Meeting Abstracts). 2015;126:abstr 130.
54. Assouline SE, Nielsen TH, Yu S, et al. Phase 2 study of panobinostat +/- rituximab in relapsed diffuse large B cell lymphoma and biomarkers predictive of response. Blood. 2016 May 10. [Epub ahead of print]
55. Liu H, Johnson JL, Koval G, et al. Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909. Haematologica. 2012;97:579-85.
56. Pott C, Hoster E, Delfau-Larue MH, et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL Intergroup study. Blood. 2010;115:3215-23.
57. Adams HJ, Nievelstein RA, Kwee TC. Prognostic value of complete remission status at end-of-treatment FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis. Br J Haematol. 2015;170:185-91.
58. Nabhan C, Smith SM, Cifu AS. Surveillance imaging in patients in remission from Hodgkin and diffuse large B-cell lymphoma. JAMA. 2016;315:2115-6.
59. Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21:922-6.
60. Newman AM, Lovejoy AF, Klass DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol. 2016;34:547-55.